You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

262 Results
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Hodgkin
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative
Funding:
New Drug Funding Program
    Brentuximab Vedotin - In Combination with Chemotherapy for Previously Untreated Advanced Stage Hodgkin Lymphoma
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
DOXOrubicin,
vinBLAStine,
dacarbazine,
brentuximab vedotin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jun 2025
Document
New
Jun 2025
Drug
Other Name(s): Tecentriq® SC
Quick Link(s): Drug Monograph, Patient Info Sheet
Jul 2025
Drug
Other Name(s): Tecentriq™
Quick Link(s): Drug Monograph, Patient Info Sheet
Jul 2025
Symptom Management
Regimen
Cancer Type:
Genitourinary, 
Prostate
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant, Curative
Funding:
ODB - General Benefit
    abiraterone
ODB - General Benefit
    prednisone
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
abiraterone,
prednisone
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jul 2025
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Myeloid (CML)
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    asciminib - For the treatment of Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase, based on criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
asciminib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jul 2025
Drug
Other Name(s): Scemblix™
Quick Link(s): Drug Monograph, Patient Info Sheet
Updated
Aug 2025
Drug
Other Name(s): Vidaza®
Quick Link(s): Drug Monograph, Patient Info Sheet
Updated
Sep 2025
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Myeloid (AML)
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative
Funding:
New Drug Funding Program
    Azacitidine in combination with Ivosidenib (Outpatient) - Previously Untreated Acute Myeloid Leukemia
Exceptional Access Program
    Ivosidenib in combination with Azacitidine (Outpatient) - Previously Untreated Acute Myeloid Leukemia
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
ivosidenib,
azaCITIDine
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
New
Sep 2025

Pages